GlassScriptPhysician profile
Steven M Minter
NPI 1649431990
$7,171.59
in general payments reported to CMS, 2019-2025
49 companies · $2,254 in 2025
The $2,254 reported for 2025 was more than what 94% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,406 · 2020: $217 · 2021: $11.92 · 2022: $1,082 · 2023: $802 · 2024: $1,400 · 2025: $2,254.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,231 · Long Term Medical Supply Or Device Loan: $1,196 · Education: $28.54.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,230.71 |
| Long Term Medical Supply Or Device Loan | $1,196.40 |
| Education | $28.54 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $2,456.42 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $486.66 | 2019-2025 | Opdivo, Opdualag, Krazati |
| Celgene Corporation | $387.63 | 2019-2025 | Reblozyl, Pomalyst |
| Janssen Biotech, INC. | $345.50 | 2019-2025 | Tecvayli, Darzalex, Talvey |
| Heron Therapeutics, INC. | $253.63 | 2022 | |
| Astellas Pharma US INC | $235.80 | 2019-2024 | Xospata, Xtandi, Padcev |
| Merck Sharp & Dohme LLC | $234.59 | 2019-2024 | Keytruda, Welireg, Reblozyl |
| Pfizer INC. | $229.15 | 2019-2025 | |
| Eagle Pharmaceuticals, INC. | $168.08 | 2022-2024 | |
| Daiichi Sankyo INC. | $158.70 | 2019-2025 | Injectafer, Enhertu, Datroway |
| Octapharma USA, INC. | $151.98 | 2022 | |
| Abbvie INC. | $149.59 | 2020-2025 | |
| Sirtex Medical INC | $148.78 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $131.75 | 2019-2024 | Ninlaro |
| Taiho Oncology, INC. | $121.80 | 2019-2020 |
Show all 49 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Emd Serono, INC. | $118.80 | 2019-2025 | Bavencio |
| Janssen Scientific Affairs, LLC | $118.73 | 2022 | |
| Array Biopharma INC | $116.12 | 2023-2025 | Mektovi, Braftovi, Tukysa |
| Gilead Sciences, INC. | $104.44 | 2021-2025 | Trodelvy |
| Adc Therapeutics America, INC. | $95.18 | 2023-2025 | |
| Rigel Pharmaceuticals, INC. | $71.03 | 2023-2025 | Rezlidhia, Tavalisse, Gavreto |
| Genentech USA, INC. | $67.15 | 2019-2022 | |
| Genzyme Corporation | $66.17 | 2019-2023 | |
| Ipsen Biopharmaceuticals, INC | $64.09 | 2019-2024 | Onivyde |
| Lilly USA, LLC | $62.04 | 2019-2022 | |
| Karyopharm Therapeutics INC. | $59.29 | 2022-2024 | Xpovio |
| Amgen INC. | $55.73 | 2019-2020 | |
| Aveo Pharmaceuticals, INC. | $51.17 | 2022-2023 | Fotivda |
| Astrazeneca Pharmaceuticals LP | $49.02 | 2019-2024 | Tagrisso |
| Mirati Therapeutics, INC. | $42.60 | 2023-2024 | Krazati |
| Incyte Corporation | $41.06 | 2023-2024 | Jakafi |
| Pharmacyclics LLC, An Abbvie Company | $27.59 | 2019-2022 | |
| Secura Bio, INC. | $27.30 | 2020 | |
| Genentech, INC. | $25.79 | 2024 | Lunsumio, Columvi |
| Jazz Pharmaceuticals INC. | $21.65 | 2024 | |
| Aurobindo Pharma USA, INC. | $21.50 | 2019 | |
| Pharmaessentia USA Corporation | $20.88 | 2025 | Besremi |
| Genmab U.S., INC. | $20.63 | 2025 | Tivdak |
| Epizyme, INC. | $17.28 | 2022 | |
| Clovis Oncology, INC. | $16.69 | 2019 | |
| Glaxosmithkline, LLC. | $16.11 | 2025 | Blenrep |
| Seagen INC. | $15.78 | 2023 | Tukysa |
| Pharmacosmos Therapeutics INC. | $14.79 | 2023 | Monoferric |
| Kite Pharma, INC. | $14.31 | 2025 | Yescarta |
| Janssen Pharmaceuticals, INC | $14.23 | 2020 | |
| Springworks Therapeutics, INC. | $14.18 | 2024 | Ogsiveo |
| Exelixis INC. | $14.06 | 2019 | |
| Kyowa Kirin, INC. | $13.54 | 2019 | |
| Helsinn Therapeutics (U.S.), INC. | $12.60 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Steven Minter listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.